• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SGS’s N.J. facility undergoes major expansion

SGS’s N.J. facility undergoes major expansion

September 25, 2012
CenterWatch Staff

SGS Life Science Services has reopened its Fairfield, N.J. facility, having just completed a major renovation that involved doubling the size of facility, investing in new, increased laboratory space, expanded client accommodation and new equipment.

The expansion enlarges the size of the facility from 15,000 to 30,000 square feet, adding completely modernized and new GMP/GLP compliant laboratories and increases ICH Zone 1-4 storage capacities. Additionally, expanded accommodation for client audits and planning sessions were implemented as part of the design. Furthermore, SGS will invest significantly on new equipment to broaden its service offering in extractables and leachables, as well as heavy metals testing.

According to John Pirro, general manager of the Fairfield site, the facility has been designed to respond to the current and future needs of a changing bio/pharmaceutical environment. He said, "This investment will provide future capacity to service the growing needs of the bio/pharmaceutical market with expanded capabilities for stability and other project work."

Anne Hays, executive vice president, SGS, said, "With outsourcing becoming an integral part of large multinational pharmaceutical companies’ strategies, we want to assure our clients that we can accommodate both their routine and complex bio/pharmaceutical analytical outsourcing needs, integrating the latest developments in regulatory compliance."

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing